表紙:感染症分子診断の世界市場・COVID-19の影響 (2021-2025年):市場予測 (症状・構成・エンドユーザー・国別)・エグゼクティブガイド・カスタム調査
市場調査レポート
商品コード
999978

感染症分子診断の世界市場・COVID-19の影響 (2021-2025年):市場予測 (症状・構成・エンドユーザー・国別)・エグゼクティブガイド・カスタム調査

Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With COVID-19 Impact & Forecasting/Analysis, and Executive Guides and Customization 2021 - 2025

出版日: | 発行: Howe Sound Research | ページ情報: 英文 497 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.49円
感染症分子診断の世界市場・COVID-19の影響 (2021-2025年):市場予測 (症状・構成・エンドユーザー・国別)・エグゼクティブガイド・カスタム調査
出版日: 2021年04月10日
発行: Howe Sound Research
ページ情報: 英文 497 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

新型コロナウイルス感染症 (COVID-19) の世界的流行により、感染症分子診断の市場は記録的な成長を示すと予測されています。

当レポートでは、世界の感染症分子診断の市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、主な感染症の概要、診断法、検査法、市場機会、市場成長の見通し、症状・構成・エンドユーザー・主要国など各種区分別の詳細分析、企業および企業間の展開、主要企業のプロファイルなどをまとめています。

第1章 感染症の分子診断:戦略的状況の分析・COVID-19の影響

第2章 企業幹部およびマーケティング・セールス・事業開発スタッフ向けガイド

第3章 経営コンサルタント・投資顧問向けガイド

第4章 イントロダクション・市場の定義

  • 分子診断とは
  • 診断の革新
  • 市場の定義
  • 調査手法
  • 米国の医療市場と臨床検査:展望

第5章 感染症の市場分析:疾患別

  • HIV:ヒト免疫不全ウイルス(AIDS)
  • HBV:B型肝炎
  • HCV:C型肝炎
  • HPV:ヒトパピローマウイルス
  • インフルエンザ
  • CTGC:クラミジア/淋病
  • 結核
  • MRSA:メチシリン耐性黄色ブドウ球菌
  • VRE:バンコマイシン耐性腸球菌
  • 血液スクリーニング
  • COVID-19
  • パンデミック診断

第6章 産業の概要

  • 参入企業
  • 市場の分類
  • 産業構造

第7章 主要企業のプロファイル

  • Abacus Diagnostica
  • Abbott Diagnostics
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Akonni Biosystems
  • Alveo Technologies
  • Applied BioCode
  • Aus Diagnostics
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • Binx Health
  • Biocartis
  • bioM?rieux Diagnostics
  • Bio:Rad Laboratories, Inc
  • Bosch Healthcare Solutions GmbH
  • Cepheid (now Danaher)
  • Chembio
  • Co Diagnostics
  • Credo Diagnostics Biomedical
  • Cue Health
  • Curetis N.V. / Curetis GmbH
  • Diagenode Diagnostics
  • Diascopic
  • Diasorin S.p.A.
  • Eiken Chemical
  • Enzo Life Sciences, Inc.
  • Eurofins Scientific
  • Fluxergy
  • Fulgent Genetics
  • Fusion Genomics.
  • Genedrive
  • Genetic Signatures
  • GenMark Dx
  • Grifols
  • Hibergene Diagnostics
  • Hologic
  • Illumina
  • Immunexpress
  • Inflammatix
  • Invetech
  • Janssen Diagnostics
  • Karius
  • Lexagene
  • LightDeck Diagnostics
  • Luminex Corp
  • Lumos Diagnostics
  • Mammoth Biosciences
  • Maxim Biomedical
  • Meridian Bioscience
  • Mesa Biotech
  • Millipore Sigma
  • Mindray
  • Mobidiag
  • Nanomix
  • Operon
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Primerdesign
  • Prominex
  • Qiagen Gmbh
  • Quantumdx
  • Quidel
  • Roche Molecular Diagnostics
  • Saw Diagnostics
  • Seegene
  • Siemens Healthineers
  • Sona Nanotech
  • SpeeDx
  • T2 Biosystems
  • Thermo Fisher Scientific Inc
  • Veramarx
  • Veredus Laboratories
  • Vir
  • XCR Diagnostics

第8章 市場動向

  • 成長促進因子
  • 成長抑制因子
  • 計装・自動化
  • 診断技術の開発

第9章 感染症の分子診断:近年の展開

  • 近年の展開・本章の使用法
  • Roche:GenMarkDiagnosticsを18億米ドルで買収
  • Lucira Health:在宅検査へのユーザーフレンドリーなアプローチに焦点
  • TalisBiomedical:IPOで2億5400万米ドルを調達
  • Fluidigm:「耐久性のある」診断、臨床ビジネスを計画
  • Thermo Fisher Scientific:最大5億5000万米ドルでMesa Biotechを買収
  • Mammoth Biosciences:病原体検出技術を開発、など

第10章 世界の感染症分子診断市場

  • 世界市場:国別
  • 症候群別
  • 構成別
  • 場所別

第11章 世界の感染症分子診断市場:症候群別

  • 呼吸器
  • 胃腸
  • 血液
  • 髄膜炎・脳炎
  • 性感染症
  • その他

第12章 世界の感染症分子診断市場:構成別

  • シングルプレックス
  • デュプレックス
  • トリプレックス
  • マルチプレックス

第13章 世界の感染症分子診断市場:エンドユーザー別

  • 病院ラボ
  • 外来ラボ
  • POC
  • その他

第14章 付録

図表

Table of Tables

  • Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2014 to 2024 ($Billion)
  • Table 2 Classifica tion of HIV Species
  • Table 3 HIV Tests - CMS Codes & Prices
  • Table 4 Current HIV Molecular Tests and Instruments Used
  • Table 5 HBV Tests - CMS Codes & Prices
  • Table 6 HCV Tests - CMS Codes & Prices
  • Table 7 HPV Clearance Rates
  • Table 8 HPV Tests - CMS Codes & Prices
  • Table 9 HPV Tests, Technology, Types
  • Table 10 Types of Influenza Tests
  • Table 11 Influenza Tests - CMS Codes & Prices
  • Table 12 FDA Cleared Molecular Assays for Influenza
  • Table 13 FDA Cleared NAAT CTGC Tests
  • Table 14 CTGC NAAT Target Sequences and Possible False Reactions
  • Table 15 CTGC Tests - CMS Codes & Prices
  • Table 16 FDA Approved MDx Tests for Tuberculosis
  • Table 17 Tuberculosis Tests - CMS Codes & Prices
  • Table 18 FDA Approved Tests for MRSA
  • Table 19 MRSA Tests - CMS Codes & Prices
  • Table 20 FDA Approved Tests for VRE
  • Table 21 VRE Tests - CMS Codes & Prices
  • Table 22 FDA Approved Multiplex Assays
  • Table 23 Characteristics of Coronavirus Pandemic Infections
  • Table 24 COVID-19 Symptoms
  • Table 25 Market Players by Type
  • Table 26 Clinical Laboratory Departments and Segments
  • Table 27 Laboratory Management Focus - Different Approaches
  • Table 28 Key Segmentation Variables Going Forward
  • Table 29 Five Factors Driving Growth
  • Table 30 Four Factors Limiting Growth
  • Table 31 Key Diagnostic Laboratory Technology Trends
  • Table 32 - Global Market by Region
  • Table 33 Global Market by Syndrome
  • Table 34 Global Market by Plex
  • Table 35 Global Market by Place
  • Table 36 Respiratory by Country
  • Table 37 Gastrointestinal by Country
  • Table 38 Blood by Country
  • Table 39 Meningitis/Encephalitis by Country
  • Table 40 Sexually Transmitted Disease by Country
  • Table 41 Other by Country
  • Table 42 Single Plex by Country
  • Table 43 Duplex by Country
  • Table 44 Triplex by Country
  • Table 45 Multiplex by Country
  • Table 46 Hospital Lab by Country
  • Table 47 Outpatient Lab by Country
  • Table 48 POC by Country
  • Table 49 Other by Country
  • Table 50 2021 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Medicare Clinical Lab Expenditures 2014 to 2024 ($Million)
  • Figure 2 HIV Virion
  • Figure 3 Diagram of the HIV Replication Cycle
  • Figure 4 The Structure of the HBV Virus
  • Figure 5 Hepatitis B Replication
  • Figure 6 Structure of the HCV Virus
  • Figure 7 HCV Replication Cycle
  • Figure 8 Structure of the Influenza Virion
  • Figure 9 Influenza Replication
  • Figure 10 Scanning Electronmicrograph of Tuberculosis
  • Figure 11 Percentage of World Population Over 65
  • Figure 12 Chart Infectious Disease Decline
  • Figure 13 Global Market Shares Chart
  • Figure 14 Global Market by Syndrome - Base vs. Final
  • Figure 15 Global Market by Syndrome Base Year
  • Figure 16 Global Market by Syndrome End Year
  • Figure 17 Syndrome Share by Year
  • Figure 18 Syndrome Segments Growth
  • Figure 19 Global Market by Plex - Base vs. Final
  • Figure 20 Global Market by Plex Base Year
  • Figure 21 Global Market by Plex End Year
  • Figure 22 Plex Share by Year
  • Figure 23 Plex Segments Growth
  • Figure 24 Global Market by Place - Base vs. Final
  • Figure 25 Global Market by Place Base Year
  • Figure 26 Global Market by Place End Year
  • Figure 27 Place Share by Year
  • Figure 28 Place Segments Growth
  • Figure 29 Respiratory Growth
  • Figure 30 Gastrointestinal Diagnostics Growth
  • Figure 31 Blood Growth
  • Figure 32 Meningitis/Encephalitis Growth
  • Figure 33 Sexually Transmitted Disease Growth
  • Figure 34 Other Growth
  • Figure 35 Single Plex Growth
  • Figure 36 Duplex Growth
  • Figure 37 Triplex Growth
  • Figure 38 Multiplex Growth
  • Figure 39 Hospital Lab Growth
  • Figure 40 Outpatient Lab Growth
  • Figure 41 POC Growth
  • Figure 42 Other Growth
目次

OVERVIEW:

COVID-19 Drives a surge in demand but what is the long term impact? The microbiology lab my disappear while multiplex takes center stage.

The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for record growth. A market that just keeps on growing but is spiking as an enormous C19Dx demand sweeps over the globe. Find out what the numbers are in this informative report. And find out about the exciting developments in multiplex assays which threaten to change diagnosis and treatment while limiting the threat of anti microbial drug resistance.

Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this new report from Howe Sound Research. A range of dynamic trends are pushing market growth and company valuations. Trends like ......

  • Multiplex testing
  • pathogen evolution and pandemics
  • biotechnology advances in genetics
  • climate change
  • globalization
  • the rise of rapid testing

Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.

All report data is available in Excel format on request.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1 Molecular Diagnostics of Infectious Disease - Strategic Situation Analysis and Impact of COVID-19.

2 Guide for Executives, Marketing, Sales and Business Development Staff

3 Guide for Management Consultants and Investment Advisors

4 Introduction and Market Definition

  • 4.1 What is Molecular Diagnostics
  • 4.2 The Diagnostics Revolution
  • 4.3 Market Definition
    • 4.3.1 Revenues
  • 4.4 Methodology
    • 4.4.1 Authors
    • 4.4.2 Sources
  • 4.5 U.S. Medical Market and Clinical Laboratory Testing - Perspective
    • 4.5.1 U.S. Medicare Expenditures for Clinical Testing

5 The Infectious Diseases - Market Analysis by Disease

  • 5.1 HIV - Human Immunodeficiency Virus (AIDS)
    • 5.1.1 Virology
      • 5.1.1.1 Classification
      • 5.1.1.2 Structure and genome
      • 5.1.1.3 Tropism
      • 5.1.1.4 Replication cycle
      • 5.1.1.5 Genetic variability
    • 5.1.2 Diagnosis
    • 5.1.3 Testing
      • 5.1.3.1 Antibody tests
      • 5.1.3.2 Point of Care Tests (POCT)
      • 5.1.3.3 Antigen Tests
      • 5.1.3.4 Nucleic acid-based tests (NAT)
      • 5.1.3.5 Other tests used in HIV treatment
    • 5.1.4 Market Opportunity Analysis
  • 5.2 HBV - Hepatitis B
    • 5.2.1 Virology
      • 5.2.1.1 Genome
      • 5.2.1.2 Pathogenesis
      • 5.2.1.3 Hepatitis B virus replication
      • 5.2.1.4 Serotypes and genotypes
    • 5.2.2 Mechanisms
    • 5.2.3 Diagnosis
    • 5.2.4 Market Opportunity Analysis
  • 5.3 HCV - Hepatitis C
    • 5.3.1 Taxonomy
    • 5.3.2 Structure
      • 5.3.2.1 Genome
    • 5.3.3 Molecular biology
    • 5.3.4 Replication
    • 5.3.5 Genotypes
      • 5.3.5.1 Clinical importance
    • 5.3.6 Market Opportunity Analysis
  • 5.4 HPV - Human papillomavirus
    • 5.4.1 Virology
      • 5.4.1.1 E6/E7 proteins
      • 5.4.1.2 Role in cancer
      • 5.4.1.3 E2 research
      • 5.4.1.4 Latency period
      • 5.4.1.5 Clearance
    • 5.4.2 Diagnosis
      • 5.4.2.1 Cervical testing
      • 5.4.2.2 Oral testing
      • 5.4.2.3 Testing men
      • 5.4.2.4 Other testing
    • 5.4.3 Market Opportunity Analysis
  • 5.5 Influenza
    • 5.5.1 Virology
      • 5.5.1.1 Types of virus
      • 5.5.1.2 Influenzavirus A
      • 5.5.1.3 Influenzavirus B
      • 5.5.1.4 Influenzavirus C
      • 5.5.1.5 Structure, properties, and subtype nomenclature
      • 5.5.1.6 Replication
    • 5.5.2 Testing
      • 5.5.2.1 Advantages/Disadvantages of Molecular Assays
    • 5.5.3 Market Opportunity Analysis
  • 5.6 CTGC - Chlamydia/Gonorhea
    • 5.6.1 Gonorrhea
      • 5.6.1.1 Diagnosis
      • 5.6.1.2 Screening
    • 5.6.2 Chlamydia
      • 5.6.2.1 Diagnosis
      • 5.6.2.2 Screening
    • 5.6.3 Testing
      • 5.6.3.1 Nucleic acid amplification tests (NAATs)
      • 5.6.3.2 Performance of NAAT Tests
    • 5.6.4 Market Opportunity Analysis
  • 5.7 Tuberculosis
    • 5.7.1 Mycobacteria
    • 5.7.2 Diagnosis
      • 5.7.2.1 Active tuberculosis
      • 5.7.2.2 Latent tuberculosis
    • 5.7.3 Epidemiology
    • 5.7.4 Molecular Diagnostic Tests
    • 5.7.5 Market Opportunity Analysis
  • 5.8 MRSA - Methicillin-resistant Staphylococcus aureus
    • 5.8.1 Diagnosis
    • 5.8.2 FDA Approved Molecular Tests
    • 5.8.3 Market Opportunity Analysis
  • 5.9 VRE - Vancomycin-resistant Enterococcus
    • 5.9.1 FDA Approved MDx Tests for VRE
    • 5.9.2 Market Opportunity Analysis
  • 5.10 Blood Screening
    • 5.10.1 Collection and Testing
    • 5.10.2 FDA Approved Multiplex Assays
    • 5.10.3 Market Opportunity Analysis
  • 5.11 COVID-19
    • 5.11.1 Signs and symptoms
    • 5.11.2 Transmission
    • 5.11.3 Diagnosis
    • 5.11.4 Prevention
    • 5.11.5 Management
    • 5.11.6 Prognosis
  • 5.12 Pandemic Diagnostics
    • 5.12.1 Risk Management - Spark and Spread
    • 5.12.2 Dx Technology - Nucleic Acid Based
    • 5.12.3 Dx Technology - Immunoassay & Serology
    • 5.12.4 Time to Market and Preparedness Issues
    • 5.12.5 Unrecognized Role of Multiplex in Pandemic Mangement

6 Industry Overview

  • 6.1 Players in a Dynamic Market
    • 6.1.1 Academic Research Lab
    • 6.1.2 Diagnostic Test Developer
    • 6.1.3 Instrumentation Supplier
    • 6.1.4 Distributor and Reagent Supplier
    • 6.1.5 Independent Testing Lab
    • 6.1.6 Public National/regional lab
    • 6.1.7 Hospital lab
    • 6.1.8 Physician Office Labs
    • 6.1.9 Audit Body
    • 6.1.10 Certification Body
  • 6.2 The Clinical Laboratory Market Segments
    • 6.2.1 Traditional Market Segmentation
    • 6.2.2 Laboratory Focus and Segmentation
  • 6.3 Industry Structure
    • 6.3.1 Hospital Testing Share
    • 6.3.2 Economies of Scale
      • 6.3.2.1 Hospital vs. Central Lab
    • 6.3.3 Physician Office Lab's
    • 6.3.4 Physician's and POCT

7 Profiles of Key MDx Companies

  • 7.1 Abacus Diagnostica
  • 7.2 Abbott Diagnostics
  • 7.3 Accelerate Diagnostics
  • 7.4 Ador Diagnostics
  • 7.5 Akonni Biosystems
  • 7.6 Alveo Technologies
  • 7.7 Applied BioCode
  • 7.8 Aus Diagnostics
  • 7.9 Beckman Coulter Diagnostics
  • 7.10 Becton, Dickinson and Company
  • 7.11 Binx Health
  • 7.12 Biocartis
  • 7.13 bioMérieux Diagnostics
  • 7.14 Bio-Rad Laboratories, Inc
  • 7.15 Bosch Healthcare Solutions GmbH
  • 7.16 Cepheid (now Danaher)
  • 7.17 Chembio
  • 7.18 Co Diagnostics
  • 7.19 Credo Diagnostics Biomedical
  • 7.20 Cue Health
  • 7.21 Curetis N.V. / Curetis GmbH
  • 7.22 Diagenode Diagnostics
  • 7.23 Diascopic
  • 7.24 Diasorin S.p.A.
  • 7.25 Eiken Chemical
  • 7.26 Enzo Life Sciences, Inc.
  • 7.27 Eurofins Scientific
  • 7.28 Fluxergy
  • 7.29 Fulgent Genetics
  • 7.30 Fusion Genomics.
  • 7.31 Genedrive
  • 7.32 Genetic Signatures
  • 7.33 GenMark Dx
  • 7.34 Grifols
  • 7.35 Hibergene Diagnostics
  • 7.36 Hologic
  • 7.37 Illumina
  • 7.38 Immunexpress
  • 7.39 Inflammatix
  • 7.40 Invetech
  • 7.41 Janssen Diagnostics
  • 7.42 Karius
  • 7.43 Lexagene
  • 7.44 LightDeck Diagnostics
  • 7.45 Luminex Corp
  • 7.46 Lumos Diagnostics
  • 7.47 Mammoth Biosciences
  • 7.48 Maxim Biomedical
  • 7.49 Meridian Bioscience
  • 7.50 Mesa Biotech
  • 7.51 Millipore Sigma
  • 7.52 Mindray
  • 7.53 Mobidiag
  • 7.54 Nanomix
  • 7.55 Operon
  • 7.56 Oxford Nanopore Technologies
  • 7.57 Panagene
  • 7.58 Perkin Elmer
  • 7.59 Primerdesign
  • 7.60 Prominex
  • 7.61 Qiagen Gmbh
  • 7.62 Quantumdx
  • 7.63 Quidel
  • 7.64 Roche Molecular Diagnostics
  • 7.65 Saw Diagnostics
  • 7.66 Seegene
  • 7.67 Siemens Healthineers
  • 7.68 Sona Nanotech
  • 7.69 SpeeDx
  • 7.70 T2 Biosystems
  • 7.71 Thermo Fisher Scientific Inc
  • 7.72 Veramarx
  • 7.73 Veredus Laboratories
  • 7.74 Vir
  • 7.75 XCR Diagnostics

8 Market Trends

  • 8.1 Factors Driving Growth
    • 8.1.1 New Genotypes Creating New Markets
    • 8.1.2 Aging Population a Boon for All Diagnostics
    • 8.1.3 Developing World Driving ID Dx Growth
    • 8.1.4 Point of Care - Why Centralization is Losing Steam
    • 8.1.5 Self Testing
    • 8.1.6 The Need for Speed
    • 8.1.7 The COVID Pandemic
  • 8.2 Factors Limiting Growth
    • 8.2.1 Lower Costs
    • 8.2.2 Infectious Disease is Declining
    • 8.2.3 Wellness Hurts
    • 8.2.4 Economic Growth improves Living Standards
  • 8.3 Instrumentation and Automation
    • 8.3.1 Instruments Key to Market Share
    • 8.3.2 The Shrinking Machine
    • 8.3.3 Multiplex, Point of Care and The Speed Factor
  • 8.4 Diagnostic Technology Development
    • 8.4.1 The Sepsis Testing Market - A New Direction?
    • 8.4.2 POCT/Self Testing as a Disruptive Force
    • 8.4.3 The Genetics Play - One Test for All Known Infections
    • 8.4.4 Antibiotic Resistance Genes - Simplifying Diagnostics

9 Molecular Dx - Infectious Disease Recent Developments

  • 9.1 Recent Developments - Importance and How to Use This Section
    • 9.1.1 Importance of These Developments
    • 9.1.2 How to Use This Section
  • 9.2 Roche to Acquire GenMark Diagnostics for $1.8B
  • 9.3 Lucira Health Focuses on User Friendly Approach to Home Testing
  • 9.4 Infectious Disease Dx Firm Talis Biomedical Raises $254M in IPO
  • 9.5 Fluidigm Plans 'Durable' Diagnostics, Clinical Business
  • 9.6 Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M
  • 9.7 Mammoth Biosciences Developing Pathogen Detection Tech
  • 9.8 Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests
  • 9.9 Scanogen Developing 90 Minute Infection Test
  • 9.10 Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection
  • 9.11 FDA Provides Self Testing SARS-CoV-2 EAU Guidance
  • 9.12 Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic
  • 9.13 Genetic Signatures Gets CE Mark for Coronavirus Molecular Test
  • 9.14 Qiagen Respiratory Panel with Coronavirus Receives CE Mark
  • 9.15 Lumos Diagnostics Closes $15M Series A Funding
  • 9.16 Fusion Genomics to Assess NGS-Based Respiratory Tract Infection Assay
  • 9.17 New Genomic Tests Diagnose Deadly Infections Faster
  • 9.18 Biotia Raises $2.4M Seed Round
  • 9.19 STDs resurge in US
  • 9.20 Ares Genetics signs R&D agreement with leading global IVD corporation
  • 9.21 Cell-Free DNA Used for Infectious Disease Testing
  • 9.22 One BioMed Raises $5M

10 The Global Market for Molecular Diagnostics Infectious Disease

  • 10.1 Global Market Overview by Country
    • 10.1.1 Table - Global Market by Country
    • 10.1.2 Chart - Global Market by Country
  • 10.2 Global Market by Syndrome - Overview
    • 10.2.1 Table - Global Market by Syndrome
    • 10.2.2 Chart - Global Market by Syndrome - Base/Final Year Comparison
    • 10.2.3 Chart - Global Market by Syndrome - Base Year
    • 10.2.4 Chart - Global Market by Syndrome - End Year
    • 10.2.5 Chart - Global Market by Syndrome - Share by Year
    • 10.2.6 Chart - Global Market by Syndrome - Segments Growth
  • 10.3 Global Market by Plex - Overview
    • 10.3.1 Table - Global Market by Plex
    • 10.3.2 Chart - Global Market by Plex - Base/Final Year Comparison
    • 10.3.3 Chart - Global Market by Plex - Base Year
    • 10.3.4 Chart - Global Market by Plex - End Year
    • 10.3.5 Chart - Global Market by Plex - Share by Year
    • 10.3.6 Chart - Global Market by Plex - Segments Growth
  • 10.4 Global Market by Place - Overview
    • 10.4.1 Table - Global Market by Place
    • 10.4.2 Chart - Global Market by Place - Base/Final Year Comparison
    • 10.4.3 Chart - Global Market by Place - Base Year
    • 10.4.4 Chart - Global Market by Place - End Year
    • 10.4.5 Chart - Global Market by Place - Share by Year
    • 10.4.6 Chart - Global Market by Place - Segments Growth

11 Global MDx Infectious Disease Markets - By Syndrome

  • 11.1 Respiratory
    • 11.1.1 Table Respiratory - by Country
    • 11.1.2 Chart - Respiratory Growth
  • 11.2 7.2 Gastrointestinal
    • 11.2.1 Table Gastrointestinal - by Country
    • 11.2.2 Chart - Gastrointestinal Growth
  • 11.3 7.3 Blood
    • 11.3.1 Table Blood - by Country
    • 11.3.2 Chart - Blood Growth
  • 11.4 Meningitis/Encephalitis
    • 11.4.1 Table Meningitis/Encephalitis - by Country
    • 11.4.2 Chart - Meningitis/Encephalitis Growth
  • 11.5 Sexually Transmitted Disease
    • 11.5.1 Table Sexually Transmitted Disease - by Country
    • 11.5.2 Chart - Sexually Transmitted Disease Growth
  • 11.6 Other
    • 11.6.1 Table Other - by Country
    • 11.6.2 Chart - Other Growth

12 Global MDx Markets for Infectious Disease - by Plex

  • 12.1 Single Plex
    • 12.1.1 Table Single Plex - by Country
    • 12.1.2 Chart - Single Plex Growth
  • 12.2 Duplex
    • 12.2.1 Table Duplex - by Country
    • 12.2.2 Chart - Duplex Growth
  • 12.3 Triplex
    • 12.3.1 Table Triplex - by Country
    • 12.3.2 Chart - Triplex Growth
  • 12.4 8.4 Multiplex Technology
    • 12.4.1 Table Multiplex - by Country
    • 12.4.2 Chart - Multiplex Growth

13 Global MDx Infectious Disease Markets - by Place

  • 13.1 Hospital Lab
    • 13.1.1 Table Hospital Lab - by Country
    • 13.1.2 Chart - Hospital Lab Growth
  • 13.2 Outpatient Lab
    • 13.2.1 Table Outpatient Lab - by Country
    • 13.2.2 Chart - Outpatient Lab Growth
  • 13.3 POC
    • 13.3.1 Table POC - by Country
    • 13.3.2 Chart - POC Growth
  • 13.4 Other Technology
    • 13.4.1 Table Other - by Country
    • 13.4.2 Chart - Other Growth

14 Appendices

  • 14.1 United States Medicare System: 2021 Clinical Laboratory Fees Schedule